Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Public ClinicalTrials.gov record NCT00558259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).
Study identification
- NCT ID
- NCT00558259
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,353 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2007 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2007
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.63.01025 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1160.63.01023 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 1160.63.01002 Boehringer Ingelheim Investigational Site | Laguna Hills | California | — | — |
| 1160.63.01014 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | — | — |
| 1160.63.01003 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 1160.63.01030 Boehringer Ingelheim Investigational Site | Key West | Florida | — | — |
| 1160.63.01022 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1160.63.01044 Boehringer Ingelheim Investigational Site | New Iberia | Louisiana | — | — |
| 1160.63.01017 Boehringer Ingelheim Investigational Site | Biddeford | Maine | — | — |
| 1160.63.01004 Boehringer Ingelheim Investigational Site | Salisbury | Maryland | — | — |
| 1160.63.01016 Boehringer Ingelheim Investigational Site | Worcester | Massachusetts | — | — |
| 1160.63.01037 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1160.63.01019 Boehringer Ingelheim Investigational Site | Missoula | Montana | — | — |
| 1160.63.01032 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1160.63.01001 Boehringer Ingelheim Investigational Site | Uniontown | Pennsylvania | — | — |
| 1160.63.01024 Boehringer Ingelheim Investigational Site | Uniontown | Pennsylvania | — | — |
| 1160.63.01005 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1160.63.01020 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1160.63.01011 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1160.63.01007 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1160.63.01035 Boehringer Ingelheim Investigational Site | Bellevue | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00558259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00558259 live on ClinicalTrials.gov.